Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 8, Pages 1573-1585
Publisher
Springer Nature
Online
2014-02-05
DOI
10.1038/leu.2014.60
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
- (2013) Tina Bagratuni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
- (2013) A. Larocca et al. BLOOD
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2013) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
- (2013) Christopher R. Flowers et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
- (2013) Philippe Rodon et al. THROMBOSIS AND HAEMOSTASIS
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
- (2012) Matthew Hoffmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- IMiD immunomodulatory compounds block C/EBP translation through eIF4E down-regulation resulting in inhibition of MM
- (2011) S. Li et al. BLOOD
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Acute Lung Toxicity Related to Pomalidomide
- (2011) Holly L. Geyer et al. CHEST
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
- (2011) M A Dimopoulos et al. LEUKEMIA
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
- (2011) Elena Zamagni et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Thrombosis in Multiple Myeloma
- (2011) S. Y. Kristinsson Hematology-American Society of Hematology Education Program
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
- (2010) J. Crawford et al. ANNALS OF ONCOLOGY
- Management of febrile neutropenia: ESMO Clinical Practice Guidelines
- (2010) J. de Naurois et al. ANNALS OF ONCOLOGY
- Multiple Myeloma
- (2010) Jacob Laubach et al. Annual Review of Medicine
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
- (2009) Y. Xu et al. BLOOD
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
- (2009) Marcio Nucci et al. CLINICAL INFECTIOUS DISEASES
- Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity
- (2009) X. Wang et al. HAEMATOLOGICA
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
- (2008) G L Uy et al. BONE MARROW TRANSPLANTATION
- Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
- (2008) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
- (2008) Matthew J. Streetly et al. BRITISH JOURNAL OF HAEMATOLOGY
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Proteasome inhibition suppresses essential immune functions of human CD4+T cells
- (2008) Carsten Berges et al. IMMUNOLOGY
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
- (2008) Ling Lu et al. MICROVASCULAR RESEARCH
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started